SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75$4.5 Million Bridge Financing led by North South VenturesComposition of Matter patent which covers over 40 potential disease...
JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive results from their...
JENKINTOWN, Pa., Jan. 11, 2023 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing new, microbiome-based therapeutics for the treatment of inflammatory diseases, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with an extension to the ongoing Phase 1b clinical trial of SFA-002, an investigational drug candidate for psoriasis. The extension will allow responders to remain on SFA-002 treatment for an additional three month period.
JENKINTOWN, PA, UNITED STATES, October 17, 2022 /EINPresswire.com/ -- SFA Therapeutics is pleased to announce that Dr. Daniel Sauder has joined our Scientific Advisory Board. Dr. Sauder brings significant experience in the development of new treatments for psoriasis and other dermatological diseases, and will be advising SFA on protocol design, development strategy and site selection. We are delighted to have Dr. Sauder join our team, as we develop SFA002, our lead drug, for psoriasis. Psoriasis is the first of several autoimmune disease indications under development for SFA002. Over 125 million people suffer from psoriasis. Despite current marketed drugs, there is still a significant unmet need for a highly efficacious oral treatment, and SFA002 has the potential to become a first-in-class oral drug for this disease. Our goal is to treat the underlying disease, not the symptoms.